Literature DB >> 11008202

Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler.

H Nakanishi1, Y Kodera, Y Yamamura, S Ito, T Kato, T Ezaki, M Tatematsu.   

Abstract

Detection of free cancer cells in the peritoneal cavity by RT-PCR using carcinoembryonic antigen (CEA) as a target gene is a more sensitive predictor of peritoneal dissemination than conventional cytology in gastric-cancer patients. Difficulties with this method are the lack of quantitative assessment of free cancer cells and the length of time before completion. To overcome these problems, we have established a rapid and quantitative detection method using a novel real-time fluorescence PCR system (LightCycler). Using this device with hybridization probes as fluorophores, we detected CEA mRNA in peritoneal washes during surgery (within 3 hr) without any post-PCR procedure. This method could reproducibly quantitate 10 to 10(6) CEA-expressing colon carcinoma cells per 10(7) peripheral blood leukocytes, a comparable sensitivity to conventional RT-PCR with a wide dynamic range. Analysis of peritoneal washes from 109 gastric-cancer patients with this assay revealed relative values of CEA transcripts that correlated well with the depth of tumor invasion (p < 0.01). Average values of CEA transcript in peritoneal washes in patients with cytology (-)/RT-PCR(-), cytology (-)/RT-PCR(+) and cytology (+)/RT-PCR(+) results were 0.64, 1,525 and 6,715, respectively. Moreover, CEA transcripts in peritoneal washes in patients with synchronous peritoneal metastasis were more than 50-fold higher than in those without metastasis. These results suggest a positive correlation between CEA mRNA levels in peritoneal washes and prognosis. We conclude that real-time RT-PCR with hybridization probes is a sensitive, quantitative, specific and rapid method to detect free cancer cells in peritoneal washes. This clinically relevant system is a powerful technique to evaluate the risk of peritoneal recurrence in patients with gastric cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11008202     DOI: 10.1002/1097-0215(20000920)89:5<411::aid-ijc3>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  32 in total

1.  Clinical importance of a transcription reverse-transcription concerted (TRC) diagnosis using peritoneal lavage fluids obtained pre- and post-lymphadenectomy from gastric cancer patients.

Authors:  Keijiro Sugimura; Yoshiyuki Fujiwara; Takeshi Omori; Masaaki Motoori; Norikatsu Miyoshi; Hirofumi Akita; Kunihito Gotoh; Shogo Kobayashi; Hidenori Takahashi; Shingo Noura; Masayuki Ohue; Takashi Yamamoto; Masato Sakon; Masahiko Yano
Journal:  Surg Today       Date:  2015-08-14       Impact factor: 2.549

2.  Prognostic significance of peritoneal lavage cytology in gastric cancer in Singapore.

Authors:  Esther W L Chuwa; Lay-Wai Khin; Weng-Hoong Chan; Hock-Soo Ong; Wai-Keong Wong
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

3.  Prognostic significance of intraperitoneal cancer cells in gastric carcinoma: detection of cytokeratin 20 mRNA in peritoneal washes, in addition to detection of carcinoembryonic antigen.

Authors:  Yasuhiro Kodera; Hayao Nakanishi; Seiji Ito; Yoshitaka Yamamura; Michitaka Fujiwara; Masahiko Koike; Kenji Hibi; Katsuki Ito; Masae Tatematsu; Akimasa Nakao
Journal:  Gastric Cancer       Date:  2005       Impact factor: 7.370

4.  New whole-body multimodality imaging of gastric cancer peritoneal metastasis combining fluorescence imaging with ICG-labeled antibody and MRI in mice.

Authors:  Akihiro Ito; Yuichi Ito; Shigeru Matsushima; Daisuke Tsuchida; Mai Ogasawara; Junichi Hasegawa; Kazunari Misawa; Eisaku Kondo; Norio Kaneda; Hayao Nakanishi
Journal:  Gastric Cancer       Date:  2013-11-28       Impact factor: 7.370

5.  Prediction of peritoneal recurrence by the mRNA level of CEA and MMP-7 in peritoneal lavage of gastric cancer patients.

Authors:  Zhen Li; Dewei Zhang; Hao Zhang; Zhifeng Miao; Yuanxin Tang; Gongping Sun; Dongqiu Dai
Journal:  Tumour Biol       Date:  2013-11-27

6.  The levels of SYT13 and CEA mRNAs in peritoneal lavages predict the peritoneal recurrence of gastric cancer.

Authors:  Koki Nakanishi; Mitsuro Kanda; Shinichi Umeda; Chie Tanaka; Daisuke Kobayashi; Masamichi Hayashi; Suguru Yamada; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2019-05-04       Impact factor: 7.370

7.  The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.

Authors:  Minkyu Jung; Hei-Cheul Jeung; Sung Sook Lee; Jun Yong Park; Soojung Hong; Soo Hyeon Lee; Sung Hoon Noh; Hyun Cheol Chung; Sun Young Rha
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

8.  Aberrant gene methylation in the peritoneal fluid is a risk factor predicting peritoneal recurrence in gastric cancer.

Authors:  Masatsugu Hiraki; Yoshihiko Kitajima; Seiji Sato; Jun Nakamura; Kazuyoshi Hashiguchi; Hirokazu Noshiro; Kohji Miyazaki
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

9.  Comparative analysis of intraperitoneal minimal free cancer cells between colorectal and gastric cancer patients using quantitative RT-PCR: possible reason for rare peritoneal recurrence in colorectal cancer.

Authors:  Masayasu Hara; Hayao Nakanishi; Qian Jun; Yukihide Kanemitsu; Seiji Ito; Yoshinari Mochizuki; Yoshitaka Yamamura; Yasuhiro Kodera; Masae Tatematsu; Takashi Hirai; Tomoyuki Kato
Journal:  Clin Exp Metastasis       Date:  2007-05-09       Impact factor: 5.150

Review 10.  Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives.

Authors:  Yoshiyuki Fujiwara; Yuichiro Doki; Hirokazu Taniguchi; Itsuro Sohma; Shuji Takiguchi; Hiroshi Miyata; Makoto Yamasaki; Morito Monden
Journal:  Gastric Cancer       Date:  2007-12-25       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.